A review in the Journal of Thoracic Oncology highlights that 8% of patients with lung cancer have pathogenic germline variants, most commonly in DNA repair genes. While not in lung cancer, the FDA approval of daraxonrasib for metastatic pancreatic adenocarcinoma is being noted as a milestone for the broader RAS-directed oncology field.
“‼️8% of patients w lung cancer have pathogenic germline variants , most commonly in DNA repair genes.”
— @Latinamd · Germline Variants in Lung Cancer · View post ↗
“This is more than a new drug. It is a major validation of RAS(ON) targeting and an important milestone for the broader RAS-directed oncology field, including lung cancer.”
— @youngkwangchae · RAS-Targeted Therapy · View post ↗📌 Amplified by @KolPulseAI
“Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update!”
— @StephenVLiu · DCLung26 Conference · View post ↗The I-SPY2 trial showed that adding the investigational dual checkpoint blockade of cemiplimab plus fianlimab to neoadjuvant chemotherapy increased pathological complete response (pCR) rates. The pCR rate was 53% versus 29% in triple-negative breast cancer (TNBC) and 36% versus 14% in HR+/HER2- breast cancer.
“I-SPY2: Adding dual checkpoint blockade with cemiplimab + fianlimab to neoadjuvant chemotherapy increased pCR rates: • Overall: 44% vs 21% • TNBC: 53% vs 29% • HR+/HER2−: 36% vs 14%”
— @Dr_ElvinaA · I-SPY2 trial results · View post ↗📌 Amplified by @KolPulseAI
BioNTech is stopping its mid-stage trial of the investigational mRNA vaccine autogene cevumeran in colorectal cancer for futility, after a review concluded it was unlikely to show an overall survival benefit in patients with resected, ctDNA-positive disease. Separately, the FDA approved daraxonrasib for second-line metastatic pancreatic cancer based on the Phase 3 RASolute 302 trial, which showed median OS improved to 13.2 months from 6.7 months (HR 0.40), reducing the risk of death by 60%.
“In Phase 3 RASolute 302, #daraxonrasib increased median OS from 6.7 to 13.2 months and reduced the risk of death by 60%.”
— @ozdogan_md · Daraxonrasib approval data · View post ↗📌 Amplified by @KolPulseAI
“The independent review committee concluded that the trial was unlikely to demonstrate an overall survival benefit, citing a numerical imbalance in survival between the treatment groups.”
— @YLeyfman · BioNTech CRC vaccine trial · View post ↗📌 Amplified by @KolPulseAI
“HR 0.40 in second-line metastatic solid tumor disease is rare anywhere. Most approvals in that setting land at 0.70 to 0.85.”
— @nlindenberg · Daraxonrasib efficacy · View post ↗📌 Amplified by @KolPulseAI
“Today's rabbit hole: tricking pMMR colorectal cancers into thinking they're dMMR, and thus making them more sensitive to immunotherapy.”
— @SeanLangenfeld · Immunotherapy in pMMR CRC · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A new guide for clinicians on Multiparametric MRI and the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer diagnosis and staging has been published. For metastatic hormone-sensitive prostate cancer (mHSPC), PTEN IHC is now available as an add-on laboratory-developed test. The GU oncology community is also highlighting the International Bladder Cancer Group's consensus paper on the optimal management of muscle-invasive bladder cancer (MIBC), which received an award for its impact.
““Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee””
— @EUplatinum · Bladder Cancer Imaging · View post ↗
“PTEN IHC, a laboratory-developed test performed by PathGroup, is now available via Tempus Hub as an add-on for patients with metastatic hormone-sensitive prostate cancer (mHSPC).”
— @TempusAI · Prostate Cancer Diagnostics · View post ↗
“Honored that our @IBCG_BladderCA consensus paper on "Optimal management of muscle-invasive bladder cancer" has received the @EUplatinum Impact Award as the most influential work in its June 2026 issue!”
— @shilpaonc · MIBC Management Consensus · View post ↗📌 Amplified by @KolPulseAI
“This weekend, on #HealthcareUnfiltered EXPRESS, spend 17 mins W the innovator & trailblazer @FaltasLab of @WeillCornell who shares with us the AI Tumor Twin concept, allowing to predict best possible therapy in urothelial cancer-paving the way to optimal clinical trials.”
— @chadinabhan · AI in Urothelial Cancer · View post ↗IMF research leaders @VincentRK and @myelomaMD propose reclassifying plasma cell leukemia as a form of high-risk myeloma to reduce confusion and expand research opportunities.
“What if plasma cell leukemia is actually only a form of high-risk myeloma? IMF research leaders @VincentRK and @myelomaMD propose reclassifying it to reduce confusion and expand research opportunities.”
— @@IMFmyeloma · Plasma Cell Leukemia · View post ↗“Think IMiD resistance is inevitable in patients with multiple myeloma? Let's talk about how CELMoDs might change that.”
— @@szusmani · CELMoDs · View post ↗The combination of ponatinib and blinatumomab (PON + BLIN) in Ph+ ALL is prompting debate over its potential to replace stem cell transplant. Commentary cautions that while results are remarkable, MRD negativity alone does not automatically mean no transplant is needed, particularly in cases with high-risk biology such as IKZF1-plus or complex cytogenetics. Other discussion reinforces that for asymptomatic CLL, adverse genetic risk alone should not be the trigger to initiate therapy.
“The results are remarkable. But MRD− does not automatically mean no transplant, particularly when the evidence in high-risk biology remains limited.”
— @HenrychihangFu1 · Ph+ ALL Transplant · View post ↗
“These findings highlight that, while genomic profiling is necessary for prognostication and treatment selection, adverse genetic risk alone should NOT prompt therapy initiation for asymptomatic #CLL.”
— @DrRaulCordoba · CLL Treatment Initiation · View post ↗